You are here: Home: PCU 2 | 2007: Case 3

Case 3

Tracks 1-2

- DR ZELEFSKY: Although this 55-year-old man refused to receive hormonal therapy or undergo surgery, I discussed with him that our standard approach is based on available studies and includes hormonal therapy. I explained the standard options because I felt he needed to hear them, even though he claimed to be well informed.

The patient had no evidence of metastatic disease. However, some bowel was located over his seminal vesicles, or in close proximity, that would make it difficult to deliver a tumoricidal dose of external beam radiation. So we treated him with a combination of brachytherapy and IMRT external beam radiation.

He completed radiation therapy about three years ago and his PSA level is approximately 0.3 ng/mL. He’s faring well, but he still has a high risk of failure and needs to be followed carefully.

- DR GOMELLA: Was the combination of brachytherapy and IMRT external beam radiation part of a study protocol, or are you offering that as standard care?

- DR ZELEFSKY: We offer the combination for locally advanced disease as standard care, not necessarily on a protocol. We have emerging protocols evaluating high-dose rate brachytherapy as monotherapy for some patients with locally advanced disease.

For a patient like this, it would have been standard to incorporate hormonal therapy, but the combination of brachytherapy and IMRT external beam radiation is a reasonable option (Zaider 2005).

- DR GOMELLA: I would like to warn that this combination should be considered cautiously. Clinicians need to recognize that Dr Zelefsky is an artist in administering external beam radiation therapy and brachytherapy. I know of some disastrous cases that are the result of patients receiving combination therapy from clinicians who do not have the skill of Dr Zelefsky.

- DR ZELEFSKY: The published literature does show more morbidity with these combination therapies, so clinicians and patients have to be cautious about this approach. If it’s done well, it’s an effective way of delivering a high dose.

Currently, the patient is doing well and has no incontinence. He does have a little more nocturia than before and remains on an alpha blocker, but his erectile function is normal and he is sexually active.

Select Publications



PCU Think Tank

Home

Table of Contents

EDITOR
Neil Love, MD

Case Discussions

CASE 1

CASE 2

CASE 3

CASE 4

CASE 5

CASE 6

CASE 7 (audio only)

CASE 8

CASE 9

CASE 10

CASE 11 (audio only)

- Select publications

Faculty Disclosures

CME Information

Editor's Office